Tools for Practice Outils pour la pratique

#335 Asymptomatic bacteriuria in the elderly: Don’t drug the bugs?

In elderly, does asymptomatic bacteriuria (ASB) cause altered mental state and will treating ASB improve clinical outcomes?

Due to important evidence limitations, it is not confirmed that ASB, or even Urinary Tract Infection (UTI), is clearly associated with altered mental state. Treating ASB does not improve clinical outcomes (including altered mental state) but may increase adverse events from 1% to 7%. In elderly patients with ASB and altered mental state, antibiotics should be avoided without clear signs/symptoms of infection. 

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • Results statistically significant unless stated.
Is any bacteriuria associated with altered mental state?
  • 3 systematic reviews (5-29 observational studies; 2630-16,618 patients).1-3
    • UTI and altered mental state:
      • Two conclude association is unclear.1,2
      • One3 reports an association odds ratio=2.67 (2.12–3.36).
      • Unreliable as UTI case-definition often includes altered mental state/delirium (without infection symptoms).1-3 Example, in one study ≥57% UTI diagnoses had no UTI symptoms.3
    • ASB and altered mental state:
      • No association in one observational study.3
Does treating ASB improve/prevent clinical outcomes?
  • 5 systematic reviews (3-9 randomized controlled trials [RCTs]; 328-1087 patients)4-8 of antibiotic treatment versus placebo/no-treatment. Most recent (9 RCTs; 1087 patients) x3-108 months:4
    • Symptomatic UTI, mortality: No difference.
    • Adverse effects (examples diarrhea, rash, candidiasis): 6.5% versus 0.7% no antibiotics.
    • Others found similar.5-8
Does treating ASB improve altered mental state?
  • RCT 58 ASB long-term care patients, norfloxacin versus placebo (7 days), followed 3-months (not included above).9
    • Mental state/function: No difference.
  • Two observational studies, 150-343 newly diagnosed delirious elderly found no difference in functional10 or delirium11 recovery when given antibiotics versus none.
Do antibiotic reduction interventions for ASB affect patient outcomes?
  • Three RCTs (2 cluster-RCTs12,13 with 22 long-term care centers 1-year each, and 214 newly admitted patients 7-days14).
    • Reducing antibiotic prescribing does not increase hospitalizations, mortality, or adverse events.12-14
  • Ordering urine culture is associated with antibiotic use.15
  • ASB is common in elderly: 5-20% in community age>80 (females>males) and institutionalization (25-50% women/15-40% men).16,17
  • ASB guidelines16 recommend:
    • Avoiding ASB treatment in elderly without clear infection signs/symptoms.
    • Assessment for other causes; careful observation; attention to contributing factors like dehydration.

Betty Ross March 8, 2023

Excellent recap and reminder

Betty Ross March 8, 2023

Good review

Janette Hurley March 8, 2023


Przemyslaw Bekasiak March 8, 2023

It confirmed what I have been doing

TAK CHAN March 9, 2023

But in the hospital the work up for delirium seems to include ruling out UTI. With this study I may reserve it to symptomatic patients other than delirium.

Dale Micoll March 9, 2023

Important information for everyone caring for elders.

Richard Coutts March 9, 2023

This is very interesting and something I will be using alot

Matthew Kalinowski March 9, 2023

Great article!

Jean Jim March 10, 2023

Good to know

Paul Salciccioli March 11, 2023

Reaffirms indication to treat

Shashi Devi March 11, 2023

I will not order Urine c/s unless needed and will not traatASB

Luc Philippe Lacroix March 13, 2023

Very useful in the elderly with fever, not to treat for UTI if no symptoms

Greg Sherman March 31, 2023

great evidence review+summary

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Jennifer Young MD CCFP-EM
  • Darren Pasay B.Sc.Pharm
  • G. Michael Allan MD CCFP

1. Mayne S, Bowden A, Sundvall PD, et al. BMC Geriatrics. 2019; 19:32.

2. Balogun SA, Philbrick JT. Canadian Geriatrics Journal. 2014; 17(1):22-26.

3. Krinitski D, Kasina R, Kloppel S, et al. J Am Geriatr Soc. 2021; 69:3312–23.

4. Krzyzaniak N, Forbes C, Clark J, et al. Br J Gen Pract. 2022; 72(722):e649-e58.

5. Henderson JT, Webber EM, Bean SI. JAMA. 2019; 322(12):1195-1205.

6. Trestioreanu AZ, Lador A, Sauerbrun-Cutler MT, et al. Cochrane Database Syst Rev. 2015; 4(4): CD009534.

7. Köves B, Cai T, Veeratterapillay R, et al. Eur Urol. 2017 Dec; 72(6):865-868.

8. Dull RB, Friedman SK, Risoldi ZM, et al. Pharmacotherapy 2014; 34(9):941–60.

9. Potts L, Cross S, MacLennan WJ, et al. Arch Gerontol Geriatr. 1996; 23(2):153-61.

10. Dasgupta M, Brymer C, Elsayed S. Arch Gerontol Geriatr. 2017 Sep; 72:127-134.

11. Joo P, Grant L, Ramsay T, et al. BMC Geriatr. 2022 Nov 29; 22(1):916.

12. Nace DA, Hanlon JT, Crnich CJ, et al. JAMA Intern Med. 2020 Jul 1; 180(7):944-95.

13. Arnold SH, Nygaard Jensen J, Bjerrum L, et al. Lancet Infect Dis. 2021; 21(11):1549-56.

14. Daley P, Garcia D, Inayatullah R, et al. Infect Control Hosp Epidemiol. 2018; 39(7):814-19.

15. Brown KA, Daneman N, Schwartz KL, et al. Clin Infect Dis. 2020; 70(8):1620-27.

16. Nicolle LE, Gupta K, Bradley SF, et al. Clin Infect Dis. 2019 May 2; 68(10):e83-e110.

17. Ariathianto Y. Australian Family Physician. 2011; 40(10): 805-9.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.